Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» KPI-121
KPI-121
Go or no go? Abbvie, Roche and Kala await key decisions
EP Vantage
Fri, 07/26/19 - 11:04 am
FDA
AbbVie
upadacatinib
Roche
Ignyta
entrectinib
Kala Pharmaceuticals
KPI-121
dry eye disease
FDA sets summer PDUFA dates for Acer, Kala therapies
BioCentury
Fri, 12/28/18 - 01:16 pm
FDA
Acer Therapeutics
Kala Pharmaceuticals
Edsivo celiprolol
KPI-121
Kala seeks FDA nod for dry eye disease drug
Drug Delivery Business News
Tue, 10/16/18 - 11:34 am
Kala Pharmaceuticals
FDA
KPI-121
dry eye disease
Kala Pharma reveals mixed Ph3 data for dry eye disease drug
Drug Delivery Business News
Fri, 01/5/18 - 05:29 pm
Kala Pharmaceuticals
dry eye disease
KPI-121